Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$14.74
$14.62
$6.38
$14.76
$1.87B0.193.08 million shs3.45 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$54.50
+0.7%
$48.22
$1.16
$14.10
$2.36B-0.12189,291 shs1.06 million shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$22.47
$22.02
$3.77
$28.00
$56.40M4.1262,902 shsN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$5.80
+0.2%
$4.74
$1.97
$22.47
N/A1.41300,068 shs77,373 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00%0.00%0.00%0.00%0.00%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00%+5.60%+16.28%+4.09%+20.92%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%-2.69%-1.86%+105.32%-69.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.8508 of 5 stars
3.43.00.00.03.31.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BELLUS Health Inc. stock logo
BLU
BELLUS Health
0.00
N/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
0.00
N/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83483.33% Upside

Current Analyst Ratings Breakdown

Latest GMTX, SLN, BLU, PFNX, and SGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BELLUS Health Inc. stock logo
BLU
BELLUS Health
$15K124,613.93N/AN/A$3.09 per share4.77
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
$12.94M4.36N/AN/A$15.68 per share1.43
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$43.26MN/AN/AN/A$4.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BELLUS Health Inc. stock logo
BLU
BELLUS Health
-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
-$43.56M-$12.23N/AN/AN/A-171.29%-83.07%-38.17%N/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)

Latest GMTX, SLN, BLU, PFNX, and SGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BELLUS Health Inc. stock logo
BLU
BELLUS Health
N/A
33.42
33.42
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/A
1.78
1.78
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
8.81
8.81

Institutional Ownership

CompanyInstitutional Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
90.37%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
N/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
BELLUS Health Inc. stock logo
BLU
BELLUS Health
24.17%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
6.50%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
BELLUS Health Inc. stock logo
BLU
BELLUS Health
74126.81 million96.16 millionNot Optionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
Sigilon Therapeutics, Inc. stock logo
SGTX
Sigilon Therapeutics
622.51 million2.35 millionNot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
100N/AN/ANot Optionable

Recent News About These Companies

Silence Therapeutics plc GAAP EPS of -C$0.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BELLUS Health stock logo

BELLUS Health NASDAQ:BLU

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$54.50 +0.37 (+0.68%)
As of 06/27/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Sigilon Therapeutics stock logo

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.80 +0.01 (+0.17%)
As of 04:00 PM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.